The transcription factor PU.1 is essential for terminal myeloid differentiation, B-and T-cell development, erythropoiesis and hematopoietic stem cell maintenance. PU.1 functions as oncogene in Friend virus-induced erythroleukemia and as tumor suppressor in acute myeloid leukemias. Moreover, Friend virus-induced erythroleukemia requires maintenance of PU.1 expression and the disruption of p53 function greatly accelerates disease progression. It has been hypothesized that p53-mediated expression of the p21
Cip1 cell cycle inhibitor during differentiation of pre-erythroleukemia cells promotes selection against p53 function. In addition to the blockage of erythroblast differentiation provided by increased levels of PU.1, we propose that PU.1 alters p53 function. We demonstrate that PU.1 reduces the transcriptional activity of the p53 tumor suppressor family and thus inhibits activation of genes important for cell cycle regulation and apoptosis. Inhibition is mediated through binding of PU.1 to the DNA-binding and/or oligomerization domains of p53/p73 proteins. Lastly, knocking down endogenous PU.1 in p53 wild-type REH B-cell precursor leukemia cells leads to increased expression of the p53 target p21 Cip1 . Oncogene (2008) 27, 3489-3493; doi:10.1038/sj.onc.1211004; published online 14 January 2008 Keywords: PU.1; p53; p73; transcriptional repression PU.1 expression and maintenance is required for normal B lymphoid and early and late myeloid differentiation. In contrast, normal erythroid development requires that PU.1 expression be temporally decreased resulting in terminal erythroid differentiation (McKercher et al., 1996; Nutt et al., 2005) . Increased PU.1 expression, either from Friend virus-induced insertional mutations in the Sfpi1 locus or by transgenic means, promotes erythroleukemia (Moreau-Gachelin, 2006) . Thus, inappropriate expression of PU.1 in erythroblasts promotes differentiation blockage. In addition to differentiation blockage, a gain of cellular proliferation is required for erythroleukemia disease progression (Moreau-Gachelin, 2006) . A recurrent genetic alteration seen in Friend tumor cells is mutations of the p53 gene (Munroe et al., 1990) . Studies using p53 null mice demonstrate that disruption of p53 function accelerates disease progression and likely supports acquisition of additional mutations (Prasher et al., 2001 ; for review see MoreauGachelin, 2006) . It has been reported that p53-dependent expression of the cell cycle inhibitor p21
Cip1 occurs during differentiation of pre-leukemic erythroblasts, perhaps contributing to selection for p53 mutations and dysfunction during progression of Friend virusinduced erythroleukemia at later stages (Kelley et al., 1998) . Alternatively, PU.1 may directly contribute to p21
Cip1 regulation or indirectly through the p53 family of tumor suppressors.
The p53 family members also include p63 and p73 that share high homology to p53, especially in the central DNA-binding domain. Full-length p63 (TAp63) and p73 (TAp73) recapitulate most p53 effects, such as growth arrest, apoptosis and differentiation, and have been shown to activate distinct target genes (Melino et al., 2002; Benard et al., 2003; Moll and Slade, 2004) . Demonstrated targets of p53 and TAp73 include p21 Cip1 , Mdm2 and Bax. Splicing at the 3 0 end leads to at least seven different TAp73 isoforms (a-y) and differential splicing and alternative promoter usage generate Nterminal truncated isoforms, termed DNp73, lacking the transactivation domain. The DNp73 isoforms mainly inhibit the transactivation activity of TAp73 and p53 proteins by oligomerization and competing for the DNA binding of the same target (Melino et al., 2002; Pluta et al., 2006) . Recent evidence shows that the DNp73 isoforms also function as transcriptional activators, such as for the BTG2TIS21/PC3 gene (Goldschneider et al., 2005) .
To determine if PU.1 is directly involved in regulating p21
Cip1
, we first evaluated whether PU.1 activated the p21 Cip1 luciferase reporter. To this end we transfected the p21
Cip1 promoter reporter with a PU.1 expression plasmid and an empty vector control into 293T cells, resulting in no activation relative to the empty expression plasmid (Figure 1a) . Coexpression of p53/TAp73a with the p21
Cip1 promoter served as positive control. As reported, the p21
Cip1 promoter was strongly induced by p53 and TAp73a, whereas PU.1 did not show any regulation ( Figure 1a ). However, coexpression of PU.1 with p53 and TAp73a markedly inhibited the induction of the p21
Cip1 promoter, from 60-to 20-fold and from 54-to 10-fold, respectively ( Figure 1a ). To assess if PU.1-mediated repression of the p53 family is exclusive to the p21 Cip1 promoter, we tested additional promoters of known p53 target genes that survey cell proliferation or apoptosis, namely hDMP1a, Bax and HIC1. hDMP1a is a tumor suppressor involved in cell cycle regulation and apoptosis via activation of ARF (Inoue et al., 1999) . The ARF protein, in turn, inactivates hMDM2 and allows p53 to accumulate and exert its growth inhibitory and proapoptotic function (Sherr and Weber, 2000) . We recently found that both the TA and DNp73 isoforms activate the hDMP1a promoter reporter. Coexpression of PU.1 with either the TA or DNp73 isoforms decreased hDMP1a activation relative to empty expression plasmid levels ( Figure 1b ). Next we tested whether PU.1 influenced Bax regulation. Bax is a proapoptotic member of the Bcl-2 family of proteins and is mainly induced upon genotoxic stress (Cory et al., 2003) . Similar to findings with p21
Cip1 and hDMP1a, we found that PU.1 expression reduced p53 activation of the Bax promoter from 19.3-to 11.3-fold and TAp73a activation of Bax was reduced from 16.5-to 14.0-fold (Figure 1c) . Lastly, we investigated if p53 activation of the HIC1 promoter is dampened by PU.1. HIC1 promotes apoptosis via inhibiting the SIRT1 deacetylase, which in turn attenuates p53 function (Chen et al., 2005) . PU.1 coexpression decreased p53 activation of the HIC1 promoter from 8.2-to 6.5-and TAp73a activation from 8.6 to 7.0-fold (Figure 1d ). To rule out the possibility that endogenous p53 and p73 present in 293T cells might influence our results, we repeated the assays using our reporter panel in p53/p73-negative H1299 non-small cell lung cancer cells. A similar pattern of inhibition of p53 target gene promoters by PU.1 was seen (data not shown). Taken together, our reporter assays clearly demonstrate that at least four known p53/73 target genes, two involved in cell growth and two in apoptosis control, are inhibited by PU.1 coexpression.
Since PU.1 alone did not regulate any of the evaluated promoter reporter panel, we speculated that PU.1 might directly interfere with the transactivation capacity of p53/p73 proteins through protein-protein interactions. 35 S-radiolabeled c-jun, p53, TAp73a, TAp73b, DNp73a and GST-PU.1. Briefly, 2 ml labeled proteins were incubated with either GST or GST fused to PU.1 for 4 h at 4 1C in NETN buffer (20 mM Tris, pH 8.0, 200 mM NaCl, 1 mM EDTA, and 0.5% NP40). GST and GST-PU.1 were recovered using glutathione-agarose beads, washed six times with NETN buffer, and separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) before autoradiography. C-jun, a known PU.1 interaction partner, was used as positive control for the GST pull-down. GST alone was used as control for unspecific binding. (d) In vivo association of PU.1 and p53. We investigated binding of endogenous PU.1 and p53 in REH lymphoblastic leukemia cells. As a negative control we used p53 wild-type, PU.1-negative MCF7 breast cancer cells. Proteins were precipitated using DO-1 monoclonal anti-p53 antibody (Calbiochem, Lucerne, Switzerland) and separated by SDS-PAGE. Western blotting was performed to detect PU.1 (SC352 anti-PU.1; Santa Cruz Biotechnologies, Santa Cruz, CA, USA) and p53. Lysates from 293T cells transiently transfected with PU.1 or p53 expression vectors served as size control for the respective western blots. (e) REH cells were transduced with lentiviral vectors expressing small hairpin (sh) RNAs targeting PU.1 (shPU.1) or a nontargeting, control shRNA (SHC002; Sigma-Aldrich, Buchs, Switzerland) as well as a puromycin antibiotic resistance gene. Transduced cells were selected in the presence of 2.5 mg ml À1 puromycin for 1 week. PU.1, p53 and p21 Cip1 mRNA was measured using real-time RT-PCR. Results are shown as n-fold regulation of SHC002-expressing cells. We found that an 80% PU.1 mRNA knockdown is paralleled by 2.7-and 2-fold induction of p21
Cip1 and p53 mRNA, respectively. (f) Strong induction of p21 Cip1 protein upon PU.1 knockdown in REH cells. Crude cell lysate were subjected to immunoblotting using anti-p21
Cip1 , -p53, -PU.1 and -actin antibodies.
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We, therefore, assessed if PU.1 binds to the p53 family proteins using the glutathione S-transferase (GST) pull-down system. To define PU.1 interaction regions we evaluated the naturally occurring p73 splice variants in our pull-down studies ( Figure 2a) . As a positive control for a protein-protein association we employed c-jun, a known PU.1 coactivator (Behre et al., 1999) . Expression, labeling and size of the in vitro transcribed and translated proteins were verified on a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE; Figure 2b ) before incubation with GST and GST-PU.1. As seen in Figure 2c , we found that all the p53 family members tested as well as c-jun were associated with PU.1, since they were only present in the GST-PU.1 and not the GST pull-downs (Figure 2c ). Since all p73 protein isoforms bind to PU.1 we can exclude the N-terminal transactivation domain, binding to DNp73a, and the sterile alpha motif (SAM) domain, binding to TAp73b, as putative PU.1 interaction domains. The DNA-binding and oligomerization domains are common to all p73 isoforms tested and highly homologous to p53 ( Figure 2a ) and therefore most likely represent the PU.1 interaction domain.
To verify that interaction of PU.1 and p53 occurs in vivo, the human B-cell precursor leukemia cell line REH, which expresses wild-type p53 as well as PU.1, was utilized (Jundt et al., 2002) . Nuclear extracts from REH and MCF7 breast cancer cells (p53 wild-type, PU.1 null) were prepared and subjected to immunoprecipitation (IP) using anti-p53 antibody, this was followed by p53 and PU.1 western blotting of the electrophoresed IP product (Figure 2d ). Although p53 is present in the IPs from REH and MCF7 cells, only the REH B cells had detectable PU.1. Our finding is consistent with PU.1-p53 interactions in a cellular environment and supports our p53 in vitro GST pull-down results.
To evaluate the consequences to endogenous p53 targets when PU.1 activity is reduced, we knocked down PU.1 in REH cells using lentiviral vector-delivered short hairpin (sh) RNA targeting PU.1. REH cells stably expressing shPU.1 displayed an 80% reduction of endogenous PU.1 as compared to control shRNA expressing cells (Figures 2e and f) . In this experiment we focused on p21
Cip1 since it was the greatest PU. 1-inhibited gene seen, and because of its defined role in erythropoiesis and stem cell proliferation (Back et al., 2004; Iwasaki et al., 2005) . We found that p21
Cip1 and p53 mRNA levels increased 2.7-and 2.0-fold, respectively (Figure 2e ). In line with the mRNA data, induction of p21
Cip1 protein upon PU.1 knockdown was seen by western blotting, whereas p53 protein only slightly increased (Figure 2f ). These novel findings further support our hypothesis where PU.1 inhibits p53 activity.
Our study describes the physical interaction of the hematopoietic transcription factor PU.1 with the p53 family of tumor suppressors. We show that PU.1 decreases p53/73 transcriptional activation of p21 Cip1 , hDMP1a, Bax and HIC1 via p53/73 DNA-binding and/ or oligomerization domains. These findings for p53 may provide an additional explanation on how aberrant and untimely expression of PU.1 in erythroblasts supports malignant transformation. In line with our hypothesis, Moreau-Gachelin et al. (1996) originally reported that PU.1 transgenic mice showed enhanced proliferation of erythroblasts that were partially blocked in differentiation. Additionally, a recent report by Rimmele et al. (2007) suggests that PU.1 has two functions in Friend erythroleukemia, blocking differentiation and an antiapoptotic function in cooperation with Epo signaling in pre-leukemic erythroblasts. The antiapoptotic function was only revealed by decreasing PU.1 expression in cells from the spi-1 transgenic mouse model for erythroleukemia. At an early stage in disease it appears that both Epo signaling and PU.1 are required for the survival of pre-leukemic erythroblasts, as the disease progresses the dependency on the survival function of PU.1 may not be as necessary. Thus, it is tempting to speculate that PU.1 inhibition of p53 might not be sufficient to promote frank leukemia, but is supportive of earlier events in pre-leukemic erythroblasts, thereby allowing a competitive advantage for survival and clonal expansion.
Furthermore, blocking p53 activity by PU.1 expression might be required to maintain a hematopoietic stem cell pool during normal development. It has been shown that PU.1 is essential for self-renewal and proliferation of hematopoietic stem and erythroid progenitor cells (Back et al., 2004; Iwasaki et al., 2005) . In addition, p21
Cip1 deficiency in HSC leads to increased proliferation and enhanced self-renewal (Cheng et al., 2000; Miyake et al., 2006) . Thus, PU.1 expression in HSC may be needed to lower p21
Cip1 expression via inhibiting p53 activity to allow proliferation of the stem cells. Moreover, a recent study described that increased PU.1 levels, from ectopic expression, are sufficient to immortalize hematopoietic progenitor cells (Houston et al., 2007) . Given these findings we propose that interaction of PU.1 with p53 is partially responsible for a gain of proliferative function and/or the cellular immortalization.
